Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist

Biological Chemistry

Volumn 394, Issue 3, 2013, Pages 353-360

  Savard, Martin ^a   Labonté, Julie ^a   Dubuc, Céléna ^a   Neugebauer, Witold ^a   D'orléans Juste, Pedro ^a   Gobeil, Fernand ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

bioassays; bradykinin analogues; cardiovascular system; metabolism; mouse

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE CARBOXYPEPTIDASE; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOLYTIC AGENT; ICATIBANT; NG291 PEPTIDE; PEPTIDE DERIVATIVE; R 954; RMP 7 PEPTIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME RELEASE; EX VIVO STUDY; FEMALE; FIBRINOLYSIS; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CHEMISTRY TECHNIQUES, SYNTHETIC; FIBRINOLYTIC AGENTS; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; PEPTIDES; PEPTIDOMIMETICS; PROTEIN BINDING; RECEPTOR, BRADYKININ B2;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 84876517534     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0295     Document Type: Article

References (53)

1. Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., and Marre, M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Curr. Pharm. Des. 17, 2654-2662.
2. Barbosa, A.M., Felipe, S.A., Pesquero, J.B., Paiva, A.C., and Shimuta, S.I. (2006). Disruption of the kinin B1 receptor gene affects potentiating effect of captopril on BK-induced contraction in mice stomach fundus. Peptides 27, 3377-3382.
3. Battegay, E.J., de Miguel, L.S., Petrimpol, M., and Humar, R. (2007). Effects of anti-hypertensive drugs on vessel rarefaction. Curr. Opin. Pharmacol. 7, 151-157.
4. Bélanger, S., Bovenzi, V., Côté, J., Neugebauer, W., Amblard, M., Martinez, J., Lammek, B., Savard, M., and Gobeil, F. Jr. (2009). Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 30, 777-787.
5. Borkowski, J.A., Ransom, R.W., Seabrook, G.R., Trumbauer, M., Chen, H., Hill, R.G., Strader, C.D., and Hess, J.F. (1995). Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. 270, 13706-13710.
6. Borlongan, C.V. and Emerich, D.F. (2003). Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: Laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull. 60, 297-306.
7. Bovenzi, V., Savard, M., Morin, J., Cuerrier, C.M., Grandbois, M., and Gobeil, F. Jr. (2010). Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J. Cell. Physiol. 222, 168-176.
8. Brown, N.J., Gainer, J.V., Stein, C.M., and Vaughan, D.E. (1999). Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33, 1431-1435.
9. Côté, J., Savard, M., Bovenzi, V., Bélanger, S., Morin, J., Neugebauer, W., Larouche, A., Dubuc, C., and Gobeil, F. Jr. (2009). Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides 30, 788-795.
10. Couture, R. and Girolami, J.P. (2004). Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur. J. Pharmacol. 500, 467-485.
11. Cruden, N.L., Lang, N.N., Macgillivray, T.J., Uren, N.G., Fox, K.A., and Newby, D.E. (2011). Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. Heart Vessels 27, 179-185.
12. Ferrari, R., Guardigli, G., and Ceconi, C. (2010). Secondary prevention of CAD with ACE inhibitors: A struggle between life and death of the endothelium. Cardiovasc. Drugs Ther. 24, 331-339.
13. Fortin, J.P., Gobeil, F. Jr., Adam, A., Regoli, D., and Marceau, F. (2003). Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor ? Am. J. Physiol. Heart. Circ. Physiol. 285, H277-282.
14. Gobeil, F., Filteau, C., Pheng, L.H., Jukic, D., Nguyen-Le, X.K., and Regoli, D. (1996). In vitro and in vivo characterization of bradykinin B2 receptors in the rabbit and the guinea pig. Can. J. Physiol. Pharmacol. 74, 137-144.
15. Gobeil, F. Jr., Charland, S., Filteau, C., Perron, S.I., Neugebauer, W., and Regoli, D. (1999). Kinin B1 receptor antagonists containing 〈 -methyl- l -phenylalanine: In vitro and in vivo antagonistic activities. Hypertension 33, 823-829.
16. Gobeil, F. Jr., Halle, S., Blais, P.A., and Regoli, D. (2002). Studies on the angiotensin-converting enzyme and the kinin B2 receptor in the rabbit jugular vein: Modulation of contractile response to bradykinin. Can. J. Physiol. Pharmacol. 80, 153-163.
17. Goodfellow, V.S., Marathe, M.V., Kuhlman, K.G., Fitzpatrick, T.D., Cuadrado, D., Hanson, W., Zuzack, J.S., Ross, S.E., Wieczorek, M., Burkard, M., et al. (1996). Bradykinin receptor antagonists containing N-substituted amino acids: In vitro and in vivo B2 and B1 receptor antagonist activity. J. Med. Chem. 39, 1472-1484.
18. Hall, J.M. (1992). Bradykinin receptors: Pharmacological properties and biological roles. Pharmacol. Ther. 56, 131-190.
19. Heitsch, H. (2003). The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin. Invest. Drugs 12, 759-770.
20. Hess, J.F., Hey, P.J., Chen, T.B., O'Brien, J., Omalley, S.S., Pettibone, D.J., and Chang, R.S. (2001). Molecular cloning and pharmacological characterization of the canine B1 and B2 bradykinin receptors. Biol. Chem. 382, 123-129.
21. Kuoppala, A., Lindstedt, K.A., Saarinen, J., Kovanen, P.T., and Kokkonen, J.O. (2000). Inactivation of bradykinin by angiotensinconverting enzyme and by carboxypeptidase N in human plasma. Am. J. Physiol. Heart Circ. Physiol. 278, H1069-1074.
22. Labont é, J., Brochu, I., Honor é, J.C., and D'Orl é ans-Juste, P. (2001). Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Br. J. Pharmacol. 132, 934-940.
23. Leeb-Lundberg, L.M., Marceau, F., M ü ller-Esterl, W., Pettibone, D.J., and Zuraw, B.L. (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77.
24. Leesar, M.A., Stoddard, M.F., Manchikalapudi, S., and Bolli, R. (1999). Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. 34, 639-650.
25. Manolis, A.J., Marketou, M.E., Gavras, I., and Gavras, H. (2010). Cardioprotective properties of bradykinin: Role of the B2 receptor. Hypertens. Res. 33, 772-777.
26. Marceau, F. (1995). Kinin B1 receptors: A review. Immunopharmacology 30, 1-26.
27. Marceau, F. and Regoli, D. (2004). Bradykinin receptor ligands: Therapeutic perspectives. Nat. Rev. Drug Discov. 3, 845-852.
28. Marceau, F., Hess, J.F., and Bachvarov, D.R. (1998). The B1 receptors for kinins. Pharmacol. Rev. 50, 357-386.
29. Marketou, M., Kintsurashvili, E., Papanicolaou, K.N., Lucero, H.A., Gavras, I., and Gavras, H. (2010). Cardioprotective effects of a selective B2 receptor agonist of bradykinin post-acute myocardial infarct. Am. J. Hypertens. 23, 562-568.
30. Minai, K., Matsumoto, T., Horie, H., Ohira, N., Takashima, H., Yokohama, H., and Kinoshita, M. (2001). Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 37, 1565-1570.
31. M ü ller-Esterl, W. (1989). Kinininogen, kinins and kinships. In: The Kallikrein-Kinin System in Health and Disease. H. Fritz, I. Schmidt, and G. Dietze, eds. (Munich, Germany: Limbach-Verlag Braunschweig), pp. 289-300.
32. Murphey, L.J., Malave, H.A., Petro, J., Biaggioni, I., Byrne, D.W., Vaughan, D.E., Luther, J.M., Pretorius, M., and Brown, N.J. (2006). Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J. Pharmacol. Exp. Ther. 318, 1287-1292.
33. Nagler, D.K., Kraus, S., Feierler, J., Mentele, R., Lottspeich, F., Jochum, M., and Faussner, A. (2010). A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int. Immunopharmacol. 10, 134-139.
34. Neugebauer, W., Blais, P.A., Halle, S., Filteau, C., Regoli, D., and Gobeil, F. Jr. (2002). Kinin B1 receptor antagonists with multienzymatic resistance properties. Can. J. Physiol. Pharmacol. 80, 287-292.
35. Nsa Allogho, S., Gobeil, F., Pheng, L.H., Nguyen-Le, X.K., Neugebauer, W., and Regoli, D. (1995). Kinin B1 and B2 receptors in the mouse. Can. J. Physiol. Pharmacol. 73, 1759-1764.
36. Nsa Allogho, S., Gobeil, F., Pheng, L.H., Nguyen-Le, X.K., Neugebauer, W., and Regoli, D. (1997). Antagonists for kinin B1 and B2 receptors in the mouse. Can. J. Physiol. Pharmacol. 75, 558-562.
37. Nsa Allogho, S., Gobeil, F., Perron, S.I., Hess, J.F., and Regoli, D. (1998). Effects of kinins on isolated stomachs of control and transgenic knockout B2 receptor mice. Naunyn Schmiedebergs Arch. Pharmacol. 357, 191-196.
38. Prasad, A., Husain, S., and Quyyumi, A.A. (1999). Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin. J. Am. Coll. Cardiol. 33, 796-804.
39. Pretorius, M., Rosenbaum, D., Vaughan, D.E., and Brown, N.J. (2003). Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107, 579-585.
40. Regoli, D., Drapeau, G., Rovero, P., Dion, S., Rhaleb, N.E., Barabe, J., D'Orleans-Juste, P., and Ward, P. (1986). Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. Eur. J. Pharmacol. 127, 219-224.
41. Regoli, D., Gobeil, F., Nguyen, Q.T., Jukic, D., Seoane, P.R., Salvino, J.M., and Sawutz, D.G. (1994). Bradykinin receptor types and B2 subtypes. Life Sci. 55, 735-749.
42. Regoli, D., Nsa Allogho, S., Rizzi, A., and Gobeil, F.J. (1998). Bradykinin receptors and their antagonists. Eur. J. Pharmacol. 348, 1-10.
43. Regoli, D., Rizzi, A., Perron, S.I., and Gobeil, F. Jr. (2001). Classification of kinin receptors. Biol. Chem. 382, 31-35.
44. Regoli, D., Plante, G.E., and Gobeil, F. Jr. (2012). Impact of kinins in the treatment of cardiovascular diseases. Pharmacol. Ther. 135, 94-111.
45. Rhaleb, N.E., Drapeau, G., Dion, S., Jukic, D., Rouissi, N., and Regoli, D. (1990). Structure-activity studies on bradykinin and related peptides: Agonists. Br. J. Pharmacol. 99, 445-448.
46. Shariat-Madar, Z., Mahdi, F., Warnock, M., Homeister, J.W., Srikanth, S., Krijanovski, Y., Murphey, L.J., Jaffa, A.A., and Schmaier, A.H. (2006). Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108, 192-199.
47. Skidgel, R.A. and Erdos, E.G. (1998). Cellular carboxypeptidases. Immunol. Rev. 161, 129-141.
48. Stewart, J.M. and Vavrek, R.J. (1991). Chemistry of bradykinin B2 antagonists. In: Bradykinin Antagonists: Basic and Clinical Research, R.M. Burch, ed. (New York: Dekker), pp. 51-96.
49. Su, J.B. (2006). Kinins and cardiovascular diseases. Curr. Pharm. Des. 12, 3423-3435.
50. Tarutani, Y., Matsumoto, T., Takashima, H., Yamane, T., and Horie, M. (2005). Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin. Hypertens. Res. 28, 59-66.
51. Wei, M., Wang, X., Kuukasjarvi, P., Laurikka, J., Rinne, T., Honkonen, E.L., and Tarkka, M. (2004). Bradykinin preconditioning in coronary artery bypass grafting. Ann. Thorac. Surg. 78, 492-497.
52. Wirth, K., Hock, F.J., Albus, U., Linz, W., Alpermann, H.G., Anagnostopoulos, H., Henk, S., Breipohl, G., Konig, W., Knolle, J., et al. (1991). Hoe 140 a new potent and long acting bradykininantagonist: In vivo studies. Br. J. Pharmacol. 102, 774-777.
53. Wirth, K.J., Linz, W., Wiemer, G., and Scholkens, B.A. (1997). Kinins and cardioprotection. Pharmacol. Res. 35, 527-530.